Hims products were shown.
Him and her
Actions Him and her health fell by more than 23% on Friday after the American food and medicine administration announced that the lack of semaglutide injection products has been solved.
Semaglutide is an active ingredient in Novo NordiskClose leaning drugs Wegova and Diabetes Treatment Ozmpic. These drugs are part of the drug class called GLP-1, and the demand for treatment has been exploded in recent years. As a result, digital health companies, such as Hims and Hers, rewrite complex semaglutide as an alternative to patients who move on unstable obstacles and insurance obstacles.
Complex drugs are non -standard alternatives for branded drugs designed to meet specific needs of the patient and can be produced when there are branded treatment lack. FDA does not assess Safety and effectiveness of complex products.
Him and her began to offer a complex semaglutide to patients in Mayand is the owner of complex pharmacies that produce medicines.
Complex drugs are usually much cheaper than their branded counterparts. Hims and it sell a semaglutide for less than USD 200, while ozempic Novo Nordisk and Wegova cost about USD 1000 without insurance.
FDA said on Friday that she would start taking action against complexes on violations in the next 60 to 90 days, depending on the type of facility, to “avoid unnecessary disruption of patient treatment.”
“Now, when the FDA has determined that the lack of drugs for semaglutide has been solved, we will continue to offer access to personalized treatment methods, in accordance with the law of satisfying the needs of patients”, Andrew Dudum, general director of Hims & Hers Posted to X Friday. “We also thoroughly monitor potential future shortages, as Novo Nordisk said two weeks ago that he will still have” capacity limitations “and” expected continuous periodic restrictions and related notifications about lack of drugs. “
The company's slimming offers were a huge hit for investors. The company's shares increased last year by over 200%, and the shares increased this year by over 100%, despite the Friday traffic.
Even before adding GLP-1S to its portfolio, the company said in its own 2023 Earnings in the fourth quarter Call that he expects his slimming program to bring over $ 100 million revenues by the end of 2025.
Despite the turbulent regulatory landscape, Hims and Hers showed no signs of slowdown.
The company on Friday announced He purchased an American peptide institution, which “will be also a vertical long -term ability of the company to provide personalized drugs.” Hims and Hers are investigating progress in metabolic optimization, nutritional sciences, biological resistance, cognitive efficiency and preventive health by taking over, The company said.
This movement will take place only a few days after Hims and Her also bought Trybe LabsA laboratory test with its registered office in New Jersey. Trybe Labs will allow him and her Make a blood draw at home and more comprehensive preliminary tests.
Him and her did not reveal the terms of any contract.
